(19)
(11) EP 0 716 596 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
03.10.2007 Bulletin 2007/40

(45) Mention of the grant of the patent:
20.06.2007 Bulletin 2007/25

(21) Application number: 94925418.9

(22) Date of filing: 29.07.1994
(51) International Patent Classification (IPC): 
A61K 9/12(2006.01)
 A61K 31/728(2006.01)
(86) International application number:
PCT/EP1994/002536
(87) International publication number:
WO 1995/003786 (09.02.1995 Gazette 1995/07)

(54)

NEW PHARMACEUTICAL COMPOSITIONS FOR TOPICAL USE CONTAINING HYALURONIC ACID AND ITS DERIVATIVES

HYALURONSÄURE UND DEREN DERIVATE ENTHALTENDE ARZNEIMITTEL ZUR TOPISCHEN ANWENDUNG

NOUVELLES COMPOSITIONS PHARMACEUTIQUES A USAGE TOPIQUE RENFERMANT DE L'ACIDE HYALURONIQUE ET SES DERIVES

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
LT SI

(30) Priority: 30.07.1993 IT PD930165

(43) Date of publication of application:
19.06.1996 Bulletin 1996/25

(73) Proprietor: FIDIA FARMACEUTICI S.p.A.
35031 Abano Terme (Padova) (IT)

(72) Inventors:
  • BENEDETTI, Luca
    I-36100 Vicenza (IT)
  • CALLEGARO, Lanfranco
    I-35020 Ponte di Brenta (IT)

(74) Representative: Jörgensson, Leif Sixten et al
Awapatent AB Box 5117
200 71 Malmö
200 71 Malmö (SE)


(56) References cited: : 
EP-A- 0 251 905
EP-A- 0 342 557
WO-A-94/15623
 EP-A- 0 265 116
WO-A-93/14129
   
  • CHEMICAL ABSTRACTS, vol. 113, no. 26, 24 December 1990, Columbus, Ohio, US; abstract no. 237840, & JP,A,02 101 010 (KASHIWA CHEMICAL CO.,LTD.) 12 April 1990
  • PATENT ABSTRACTS OF JAPAN vol. 018, no. 140 (C-1177) 8 March 1994 & JP,A,05 320 055 (DENKI KAGAKU KOGYO KK) 3 December 1993
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).